<div id="readability-page-1">Needham on Friday launched its coverage of Astrana Health (ASTH) with a Buy recommendation and a $28 price target, citing a valuation disconnect between hospitals and the health tech firm, which helps providers participate in value-based care (VBC). According to analyst Matthew Shea, Astrana’s (ASTH) current trading level of ~6x in terms of 2026 EB...</div>

ASTH

<p>Needham 對 Astrana Health (ASTH) 啓動了覆蓋，給予 “買入” 評級，目標價為 28 美元，理由是醫院與該健康科技公司之間存在估值脱節。分析師 Matthew Shea 指出，Astrana 目前的交易水平低於醫院運營商，認為其股票被低估。他強調了公司將醫院運營整合到其基於價值的護理網絡中的能力，以及其卓越的增長潛力和利潤空間</p>

Needham 基於估值首次給予 Astrana Health 買入評級